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Available online 18 September 2014Androgen receptor genemutations are one of the leading causes of disorders of sex development (DSD) exhibited
by sexual ambiguity or sex reversal. In this study, 2 familieswith patients whomdiagnosed clinically as androgen
insensitivity syndrome (AIS)were physically and genetically examined. This evaluation carried out by cytogenet-
ic andmolecular analysis including karyotype and sequencing of SRY and AR genes. In family 1, two brothers and
their motherwere hemizygous and heterozygous respectively for c.2522G N A variant, while one of their healthy
brother was a completely normal hemizygote. Family 2 assessment demonstrated the c.639G N A (rs6152)
mutation in two siblings who were reared as girls. The SRY gene was intact in all of the study's participants.
Our ﬁndings in family 1 could be a further proof for the pathogenicity of the c.2522G N A variant. Given the im-
portance of ARmutations in development of problems such as sex assignment inAIS patients, deﬁnitive diagnosis
and phenotype–genotype correlation could be achieved bymolecular genetic tests that in turn could have prom-
ising impacts in clinical management and also in prenatal diagnosis of prospect offspring.
In this regard, phenotype–genotype correlation could be helpful and achieved by molecular genetic tests. This
could inﬂuence the clinical management of the patients as well as prenatal diagnosis for the prospective
offspring.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Mutations in AR gene may lead to perturbation in the uptaking of
androgen and subsequent Androgen Insensitivity Syndrome (AIS) by
the effect of insufﬁcient intracellular androgenic response. There are
various AIS phenotype patients' varieties i.e. from isolated infertility inn insensitivity syndrome; AR,
ity; DHT, Dihydrotestosterone;
ment; EDTA, Ethylene diamine
D, Ligand binding domain; LH,
al androgen insensitivity; PCOS,
tion; PGD, Pre-implantation ge-
natal diagnosis; SRY, Sex region
lfate; A2, Androstenedione.
koly-Bazzaz).less severe type of Partial Androgen Insensitivity Syndrome (PAIS) to
Complete Androgen Insensitivity Syndrome (CAIS) manifested by fe-
male phenotype. The prevalence of CAIS is about 1 in 40,000–60,000
birth (Brinkmann, 2001). All AIS patients regardless of phenotype sever-
ity show 46 XY karyotype, and the absence of Mullerian derived struc-
tures including fallopian tubes, uterus and cervix with normal
testicular pathology found beyondphysical, paraclinical and cytogenetic
examinations. Based on the Quigley et al. outline, there are 1–5 degrees
of AIS in which the ﬁrst degree corresponds CAIS and the 2–5 degrees
are in relation with the wide diversity in clinical presentations of PAIS.
CAIS is diagnosed based on the complete female appearance and breast
development during puberty along with undescendent testes with or
without epididymis and vas deferens. PAIS grade 1 (degree 2 of AIS)
could predominantly be considered in female cases and is easily distin-
guished from CAIS by the presence of clitoromegaly or labial fusion. In
the third degree of PAIS however, in addition to gynecomastia,
clitoromegaly develops more into a penis with the length of less than
Table 1
Primer list used fro AR gene mutation detection.
Primer Sequence
Ex1a-F 5′-AGG GAA GTA GGT GGA AGA TTC AG-3′
Ex1a-R 5′-CCT CGC TCA GGA TGT CTT TAA G-3′
Ex1b-F 5′-CCC CAC TTT CCC CGG CTT AAG-3′
Ex1b-R 5′-GCA CTG GAC GAG GCA GCT GCG-3′
Ex1c-F 5′-TCC GGG ACA CTT GAA CTG CCG-3′
Ex1c-R 5′-TGC CCT GGG CCG AAA GGC G-3′
Ex2-F 5′-AAT GCT GAA GAC CTG AGA CT-3′
Ex2-R 5′-AAA ATC CTG GGC CCT GAA AG-3′
Ex3-F 5′-CTA GAA ATA CCC GAA GAA AG-3′
Ex3-R 5′- GAG AGA CTA GAA AAT GAG GG-3′
Ex4-F 5′-GTG ATT TTC TTA GCT AGG GC-3′
Ex4-R 5′-ATC CCC CTT ATC TCA TGC TC-3′
Ex5-F 5′-GAC TGA CCA CTG CCT CTG CC-3′
Ex5-R 5′-TCA CCC CAT CAC CAT CAC CA-3′
Ex6-F 5′-TGT AAA CTT CCC CTC ATT C-3′
Ex6-R 5′-TAA TGG CAA AAG TGG TCC TC-3′
Ex7-F 5′-TGT GGT CAG AAA ACT TGG TG-3′
Ex7-R 5′-CTC TAT CAG GCT GTT CTC CC-3′
Ex8-F 5′-GCC ACC TCC TTG TCA ACC CT-3′
Ex8-R 5′-AGA GGA GTA GTG CAG AGT TA-3′
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labiamajora recognized as biﬁd scrotum. AIS patients are predominant-
ly male in 3rd grade of PAIS phenotype and exhibit hypospadias with
normal or small size of penis, descendent or undescendent testes and
gynecomastia. The last but least severe type of PAIS [mild AIS (MAIS)]
patients may solely indicate spermatogenesis defects and gynecomastia
with mild impaired virilization (Quigley et al., 1995). Although geno-
type–phenotype correlation is not strong in AIS, this clinical heteroge-
neity is in contingency with the domain of protein that has been
mutated (Balducci et al., 1996; Chu et al., 2002) and ﬁnding this corre-
lation would help to better diagnose AIS patients. Contrary to CAIS, in
molecular analysis of more than 50% PAIS patients a distinct AR gene
mutation was not found (Ahmed et al., 2000; Morel et al., 2002). How-
ever, it seems AR mutation evaluation is preferable to other diagnostic
tests like IHC in the evaluation of individuals with AIS phenotype
because of its simplicity in sample preparation. In that AIS phenotype
is apparent which is highly signiﬁcant in AIS pathogenesis. Biochemical
and paraclinical tests including pelvic ultra sound and genetic analysis
complete the pyramid in AIS diagnosis.
Androgen receptor (AR) protein that is encoded by AR gene is locat-
ed on chromosome Xq11–12 that contains 8 exons. It is the fourth
member of group C classiﬁcation belonged to the sub-classiﬁcation of
3 nuclear steroid receptors super family and is involved in the develop-
ment and differentiation of male sexual characteristics (McPhaul et al.,
1991). More than 500 various types of mutations have been reported
in AR gene,which is the leading cause ofmale sexderivation in the spec-
trum of diseases called disorders of sex development (DSD). Among all
of the putative mutations, point mutations comprise the most common
type of alterations in pathologic conditions related to AR gene (Quigley
et al., 1995).
Sex dissatisfaction and other psychologically related problems in
these patients demand the investigation of AR gene mutation and its
role in this issue. Although the reports are controversial in both sexes.
2. Patients and methods
2.1. Patients
This study was carried out on two Iranian families affected by AIS
diagnosed on the basis of clinical presentations, biochemical and
screening discoveries. The informed consent forms were ﬁlled up by
every family member. Progesterone, 17-OH progesterone, DHEA-S,
androstenedione (A2), testosterone (T), dihydrotestosterone (DHT)
and estradiol were measured at 08:00 am in patients whose FSH and
LH levels were high and subsequently after hCG test in case the patients
were prepubertal. The ratios of T/DHT and T/A2were calculated. The ra-
tios of T/DHT N 20 and T/A2 b 0.8 were considered as 5α reductase and
17β-hydroxysteroid dehydrogenase type 3 deﬁciency, respectively
(Dattani et al., 2011).
2.2. DNA extraction and karyotype
Six milliliters of whole blood was taken from every family member
and 4 mL of it was transferred into tubes containing 200 μL EDTA for
DNA isolation. The remaining 2 mL of whole blood was preserved in
tubes containing heparin to be used for karyotype examination. DNA
was isolated from peripheral blood of all samples by standard salting
out method. The quality and concentration of the genomic DNA were
determined through PCR products in (1.5%) gel electrophoresis and
spectrophotometer respectively. The karyotype of all the patients en-
rolledwas determined through cell culture and subsequent preparation
of chromosome ideogram according to the common method of G-
banding. It is comprised of cell culturing, harvesting and slide prepara-
tion. The slideswere GTGbanded and examined under lightmicroscope
and 20 chromosome spreads were examined.2.3. Polymerase chain reaction (PCR) and sequencing
The exons 1–8 of AR gene residing on chromosome Xq12 were am-
pliﬁed using 10 primer pairs designed via Primer 3 software (http://
frodo.wi.mit.edu/primer) (Table 1). PCR reaction was incurred in a
25 μL reaction mixture including 50 ng of each genomic DNA template.
The mixture consisted of 20 mmol/L Tris–HCl pH 8.4, 50 mmol/L KCl,
1 mmol/L MgCl2, 10 pmol for each primer, 0.2 mmol/L for each dNTP
mixture and also 1.25 units of Smart Taq DNA polymerase Fermentas,
(Canada). After initial denaturation at 94 °C for 5 min, 37 PCR cycles
was performed using Biorad thermocycler (Bio-Rad Laboratories, Her-
cules, CA, USA); each cycle included denaturation at 95 °C in 30 s, an-
nealing at 60 °C in 30 s, extension at 72 °C for 30 s and ﬁnal extension
at 72 °C in 5 min. However, the mentioned annealing temperature
was changed to 55 °C, 58 °C and 63 °C for exons 3, 4 and 7 respectively.
The single exon of SRY gene on chromosome Yp11.3 was ampliﬁed
using one pair of forward and reverse SRY speciﬁc primer for sequence
analysis (Table 2). Each 25 μL PCR reaction contained 20 mmol/L Tris–
HCl pH 8.4, 50 mmol/L KCl, 2 mmol/L MgCl2, 10 pmol of each primers,
0.2 mmol/L of each dNTPmix, 1.25 units of Smart Taq DNA polymerase
(Fermentas) and 50 ng of genomic DNA. Ampliﬁcation was also carried
out on using thermal cycler (Corbet, USA) with an initial 7-minute de-
naturation at 96 °C, followed by 35 PCR ampliﬁcation cycles of denatur-
ation at 95 °C for 30 s, annealing at 56 °C for 60 s, elongation at 72 °C for
45 s, and extension at 72 °C for 10min respectively. PCR products were
subjected to electrophoresis on agarose gel (1.5%) followed by staining
with ethidium bromide (1 μg/mL) to verify anticipated length of ampli-
ﬁed fragments. Direct sequencing was used with primers (Table 2) to
observe AR and SRY gene sequences alterations in each patient.
Sequencing was carried out by MACROGEN company in South Korea
using classic Sanger method with ABI. The analyzing of raw data was
performed by Gene Marker software.
2.4. Immunohistochemistry (IHC)
The genital skin biopsies of IV1 and IV2 for the ﬁrst family were em-
bedded in parafﬁn. IHC for AR protein was performed on 5 μm sections
using Pharm Dx immunohistochemistry kit (Dako, Cambridge, UK).
3. Results
Genitalia phenotype in siblings (two brothers) for the ﬁrst family
indicated microphallus, hypospadiasis, bilateral cryptorchidism and gy-
necomastia. Additional examinations by ultrasound also manifested
Table 2




5′-TTT CAA TTT TGT CGC ACT CTC C−3′ SRY2-F
5′-AAA GTG AGG GCT GTA AGT TAT C-3′ SRY2-R
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grade III PAIS. Genitalia phenotype of siblings (two sisters) manifested
completely female and consequently diagnosed as CAIS. Further evalua-
tions using ultrasound demonstrated two inguinal undescendent testes
which had been removedby surgery as a prophylaxis of gonadoblastoma.
The results of cytogenetic study featured 46, XY karyotype for patients
signifying the male chromosomal sex. The ratios of T/DHT and T/A2
were normal and the level of precursors of testosterone was not high
either after hCG test or after puberty and the level of testosterone was
normal in all patients. The single exon of SRY gene was intact and free
of either mutation or polymorphism in all examinations. In family 1
(Fig. 1), both patients were hemizygote for c.2522G N A variant which
is responsible for the replacement of arginine residue by histidine.
Genotyping of their normal brother conﬁrmed his normal phenotypes,
albeit theirmotherwas identiﬁed as heterozygote for the same alteration
(c.2522G N A). In family 2 (Fig. 2), molecular analysis revealed c.639G N A
variant, hemizygote state in both affected assigned sisters. Their mother
was a homozygote for this variant in which the glutamic acid amino
acid remained unchanged. The IHC test of the genital skin cells showed
weak positive results also detected in IV1 and IV2 members of family 1
(Fig. 3).
4. Discussion
Sex dissatisfaction and other psychologically related issues have sig-
niﬁcant role in sex changes determination such as AIS. Various studies
have shown controversial results in sex satisfaction whether in respect
to males or females.
According to Diamond et al., CAH patients who underwent feminiz-
ing genital surgery have demonstrated poor sexual function and satis-
faction. Sexual dissatisfaction was evident in 25% of DSDs including
PAIS whom were reared as male or female (Migeon et al., 2002a).
Mazur et al. have demonstrated that some of the patients with PAIS
had the same dissatisfaction regardless of their sex has been changed
to either male or female (Mazur, 2005). However, in present study,Fig. 1. Left: Family 1 pedigree; right: DNA sequence chromatograms in exon 7 of the AR gene f
statue of mother and the homozygote genotype of her two sons.the medical interventions in order to help gender development toward
male in affected cases of family 1 have failed to bring sex fulﬁllment.
IHC and genetic molecular tests are being used for PAIS diagnosis.
Considering the invasiveness of sample providing for IHC technique ge-
netic molecular test is preferred since as well as not being invasive, it is
more informative in comparison. Therefore, the geneticmolecular test is
preferred as the sampling is not invasive and the results are more infor-
mative compared to the IHC test.
IHC result of two PAIS patients in family 1 was weakly positive,
which to some extent explains the partial phenotypes of these patients,
suggesting that the aberrant AR protein still could stimulate the andro-
genic response. In the next step, we identiﬁed the 2225G N A (R841H or
rs9332969) variant detected within helice 9 LBD domain of AR protein
encoded by exon 7 in the two brotherswith the similar phenotype com-
patible for PAIS manifestation. The outcomewas the replacement of ar-
ginine by histidine in residue 841. Also, to examine the pathogenicity of
this variant, DNA analysis and sequencingwere performed on one of the
normal siblings of this family and his mother for AR mutations. It has
been reported that the arginine residue of 841 together with 774, 855,
and 866 residues constitutes four hot spots in AR gene, which accounts
for 25% of all missense mutations residing in AR gene (Wilson et al.,
1974; Maes et al., 1980; Batch et al., 1993). Further, R841Hmutation in-
ﬂuences the binding and interaction of AR protein in its receptor
(LundbergGiwercman et al., 1998). Accordingly, LBD domainmutations
were detected in a patient with genital ambiguity with very low andro-
gen binding capacity (De Bellis et al., 1994), that further can indirectly
lead to a decrease in AR mediated transcription activity of target genes
through impairing the ligand binding activity and increase AR protein
recycling (Omrani and S. G. S., 2006).
Based on this and similar studies, it can be suggested that R841H ex-
change is often in relation with PAIS, not CAIS, which means that the
substitution is insufﬁcient for the total AR function disruption. There-
fore, it seems that R841H mutation which was observed within the he-
lice 9 of LBDdomain of AR protein is in correlationwith PAIS phenotype.
In this regard, the diagnosis of every patient with genital ambiguity
through AR gene examinations especially LBD domain at birth, could
pave the way for early detections and more practical management. By
the assessment of different types of DSDs in more than 90 cases, Migeon
et al. recommended that thedetection of mutations within the AR gene
can be themain basis of PAIS diagnosis (Migeon et al., 2002b). Therefore,
the early diagnosis of PAIS bymolecular genetic tests during the ﬁrst few
weeks of life assists in better decision making and sexual identity cares.
However, in family 2 (sibling sisters and mother), G639A exchange
was present. G639A variation resides within the AF2 segment of NTDor the affected sibling brothers; one normal sibling and their mother indicating the carrier
Fig. 2. Left: Family 2 pedigree; right: DNA sequence chromatograms of exon 1 of the AR gene related to the two affected sisters and theirmother demonstrating the homozygote statue for
mother and her actual two daughters.
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scription activity of AR. This synonymous and probably non-pathogenic
variant was described before in a Brazilian family with ﬁve AIS patients
(Melo et al., 2003). However, it has been reported in association with a
related but not such close disease with AIS such as polycystic ovary syn-
drome (Lundberg Giwercman et al., 1998). Detecting the same ﬁnding
in sequence analysis of the mother of family 2 (Fig. 2) which clariﬁed
that this polymorphism might have no effect on clinical presentations
of her two sons. In addition, AR protein NTD domain has strong ability
to be compatible withmost of the single base pair substitutionswithoutFig. 3. Left: Histopathology features of skin tissue stained by H& E within unremarkable
skin; Right: IHC staining of the same specimen for androgen receptor shows weakly pos-
itive result in IV1 and IV2 patients of family 1.any negative impacts on AR functioning. However, in this domain, large
deletions or aggregation ofmultiple variations are required for AR activ-
ity impairment. AR has indicated without anymissensemutations in 5%
of CAIS and 27% to 72% of PAIS patients (Ahmed et al., 2000; Melo et al.,
2003; Galani et al., 2008; Ferlin et al., 2006).
The presence of same phenotype in both siblings of family 2 could
propose that the genetic inﬂuence for CAIS is quite signiﬁcant. It was
shown that the presence of unknown co-activators is required for the
transmission of expression signal from AF-1 to basal transcription ma-
chinery. The lack of these co-activators could lead to PAIS presentation
despite the AR gene would be intact (Horwitz et al., 1996). Some of
the co-activators interacting with AF-2 region were determined includ-
ing p300, androgen receptor-associated protein, transcriptional inter-
mediary factor 2 and full-steroid-receptor co-activator-1. Since the
G639A is a synonymous variant, its probable associationwithmutations
of unidentiﬁed AF-1 co-activators could explain such abnormal clinical
phenotype. Further studies are needed to determine AR co-activators
that interact with AF-1 to shed light on the pathophysiology of AIS
among AR mutation free cases.
Genetic counseling plays a crucial role in management of X-linked
disorders such as AIS. There are various approaches to AIS genetic
counseling and related family members. Sex selection through pre-
implantation genetic diagnosis (PGD) or prenatal diagnosis (PND)
could be recommended for families with unknown mutation. In cases
with known mutation, the conﬁrmation of diagnosis is possible via di-
rect molecular analysis through PGD or PND.
It should be noted that the improper or late diagnosis may expose
AIS patients to the development of gonadoblastoma tumors, prostate
cancer — particularly in carriers of LBD alterations and problems in
socio-sexual identity (Gottlieb et al., 2004). In the consideration of pu-
berty virilization putative occurrence, gonadectomy should be per-
formed prior teenage (Kohler et al., 2005).
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Our ﬁndings in family 1 could be a further proof for the pathogenic-
ity of the “c.2522G N A variant”. The c.639G N A (rs6152) variant in two
siblings in family 2 could not be conﬁrmed as the cause of disease. We
suggest that the R841Hmutation of LBDdomain of ARprotein correlates
with PAIS phenotype. On the basis of clinical examinations, different
molecular methods are employed to conﬁrm PAIS diagnosis. In IHC
the antigenic property of protein is targeted by assay. In molecular ge-
netic testing any delicate changes of protein structure correspondent
to nucleotide changes can be recognize by a simple, non-invasive and
more accurate method. Therefore, the mutation screening of a sub re-
gion of AR protein, the LBD domain, could be considered as a crucial
step in suspicious PAIS subjects. Since the early diagnosis of PAIS in chil-
drenwithDSD is highly needed for appropriate choosing of rearing gen-
der, such molecular analysis could prevent undesired outcomes and
pave the way for genetic counseling. According to our personal experi-
ence, for grade III to V PAIS, the gender change toward female against
chromosomal sexuality would be more reasonable.
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